Type of information: Grant
Company: OSE Immunotherapeutics (France)
Investors: FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France
Funding type: grant
- The grant will support the HybridADCC project. This collaborative research project will identify novel monoclonal antibodies and develop an innovative and standardized test that measures the ability of therapeutic antibodies to destroy tumour cells (or infected cells) through a mechanism of toxicity called Antibody - Dependent Cell-mediated Cytotoxicity (ADCC). The research will be conducted
by OSE Immunotherapeutics, Clean Cells (leader of the consortium), INSERM (UMR1232-CNRS ERL6001, Nantes), and the MicroPICell Federative Research Structure François Bonamy (Nantes).
- Through this research project, OSE Immunotherapeutics will have access to a platform to identify, to develop and to validate cytotoxic antibodies targeting new product candidates in immuno-oncology. One of the product candidates to be evaluated is OSE Immunotherapeutics’ cytotoxic antibody, OSE-703, currently being explored in lung cancer by Dr. Prasad Adusumilli’s team at Memorial Sloan Kettering Cancer Center in New York. The HybridADCC program also will evaluate the in vitro efficacy of OSE-703 inother cancers of interest.
- • On December 14, 2017, OSE Immunotherapeutics announced that the company will receive a €398,000 grant from the “Fonds Unique Interministériel” (FUI), dedicated to the financing of competitiveness cluster projects, to identify new monoclonal antibodies and therapeutic targets. Out of a total project cost of €2.4 million, the FUI is providing €1.2 million to fund this research that will be conducted by OSE Immunotherapeutics, Clean Cells (leader of the consortium), INSERM (UMR1232-CNRS ERL6001, Nantes), and the MicroPICell Federative Research Structure François Bonamy (Nantes).
Therapeutic area: Cancer - Oncology